Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Giang, E.
  • Dorner, M.
  • Prentoe, J. C.
  • Dreux, M.
  • Evans, M. J.
  • Bukh, J.
  • Rice, C. M.
  • Ploss, A.
  • Burton, Dennis
  • Law, Mansun

publication date

  • April 2012

journal

  • Proceedings of the National Academy of Sciences of the United States of America  Journal

abstract

  • Hepatitis C virus (HCV) infects ∼2% of the world's population. It is estimated that there are more than 500,000 new infections annually in Egypt, the country with the highest HCV prevalence. An effective vaccine would help control this expanding global health burden. HCV is highly variable, and an effective vaccine should target conserved T- and B-cell epitopes of the virus. Conserved B-cell epitopes overlapping the CD81 receptor-binding site (CD81bs) on the E2 viral envelope glycoprotein have been reported previously and provide promising vaccine targets. In this study, we isolated 73 human mAbs recognizing five distinct antigenic regions on the virus envelope glycoprotein complex E1E2 from an HCV-immune phage-display antibody library by using an exhaustive-panning strategy. Many of these mAbs were broadly neutralizing. In particular, the mAb AR4A, recognizing a discontinuous epitope outside the CD81bs on the E1E2 complex, has an exceptionally broad neutralizing activity toward diverse HCV genotypes and protects against heterologous HCV challenge in a small animal model. The mAb panel will be useful for the design and development of vaccine candidates to elicit broadly neutralizing antibodies to HCV.

subject areas

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibody Specificity
  • Antigens, CD81
  • Cell Line, Tumor
  • Enzyme-Linked Immunosorbent Assay
  • Epitopes, B-Lymphocyte
  • Genotype
  • HEK293 Cells
  • Hepacivirus
  • Hepatitis C
  • Hepatitis C Antibodies
  • Humans
  • Immunoblotting
  • Mice
  • Molecular Sequence Data
  • Peptide Library
  • Viral Envelope Proteins
  • Viral Hepatitis Vaccines
scroll to property group menus

Research

keywords

  • antigenic determinant
  • chronic viral infection
  • cross-neutralizing antibody
  • protective determinant
  • virus challenge
scroll to property group menus

Identity

PubMed Central ID

  • PMC3341081

International Standard Serial Number (ISSN)

  • 0027-8424

Digital Object Identifier (DOI)

  • 10.1073/pnas.1114927109

PubMed ID

  • 22492964
scroll to property group menus

Additional Document Info

start page

  • 6205

end page

  • 6210

volume

  • 109

issue

  • 16

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support